JHL Biotech gets positive CHMP scientific advice for phase III trial of proposed trastuzumab biosimilar to treat breast cancer

JHL Biotech has received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the EU approval pathway

More From BioPortfolio on "JHL Biotech gets positive CHMP scientific advice for phase III trial of proposed trastuzumab biosimilar to treat breast cancer"